A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
Inclusion Criteria:
Exclusion Criteria:
Salt Lake City, Utah 84132, United States
Burlington, Vermont 05401, United States
Vienna, 1090, Austria
Varna, 9002, Bulgaria
Göttingen, 37075, Germany
Mainz, 55131, Germany
Rome, Lazio 00198, Italy
Milan, Lombardy 20100, Italy
Perugia, Umbria 06129, Italy
Hokkaido, 060-8648, Japan
Hokkaido, 078-8510, Japan
Moscow, 119435, Russia
Santiago de Compostela, LA Coruña 15706, Spain
Las Palmas de Gran Canaria, LAS Palmas 35016, Spain